
-
Tango Therapeutics NASDAQ:TNGX Tango Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops drugs and medicines for the treatment of patients. Tango Therapeutics serves customers in the State of Massachusetts.
Location: | Website: www.tangotx.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-2.146M
Cash
293.3M
Avg Qtr Burn
-30.58M
Short % of Float
11.84%
Insider Ownership
8.46%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TNG260( CoREST complex inhibitor) w/ pembrolizumab Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
TNG462 ( PRMT5 inhibitor) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
TNG908 ( PRMT5 inhibitor) Details Cancer, Solid tumor/s, Glioblastoma | Phase 1/2 Update | |
TNG456 ( PRMT5 inhibitor) +/- abemaciclib Details Cancer, Solid tumor/s | Phase 1/2 Initiation | |
TNG348 (USP1 inhibitor) Details Cancer, Ovarian cancer, Breast cancer, Prostate cancer, Pancreatic cancer | Failed Discontinued |